A Crossover Study of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
Recruiting Phase 4 NCT06195241
Study Description
Testing the Effects of a New Botulinum Toxin (DaxibotulinumtoxinA) in Patients with Blepharospasm and Hemifacial Spasms
Study Details
- Registry ID:
- NCT06195241
- Conditions:
- Benign Essential Blepharospasm, Hemifacial Spasm
- Phase:
- Phase 4
- Target Enrollment:
- 40 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Montefiore Medical Center
Bronx, New York, United States -
Montefiore Medical Center
The Bronx, New York, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.